"Le Centre Hospitalier Agen-Nérac est le premier établissement public de santé de Lot-et-Garonne. De par sa taille et du fait de ses missions, il est l’hôpital de recours pour un bassin de de 110 000 habitants et qui s’entend sur les départements limitrophes. Au service de la santé des usagers et du territoire, il est l’établissement support du GHT de Lot-et-Garonne. Chaque jour, nos professionnels de santé assurent des soins préventifs, éducatifs, curatifs ou palliatifs ainsi que la réalisation d’examens de diagnostic pour les personnes dont l’état de santé le nécessite, sans aucune discrimination : tel est notre mission de service public."

During the past decade, CH Agen conducted 21 clinical trials. In the 10-year time frame, 21 clinical trials started and 5 clinical trials were completed, i.e. on average, 23.8% percent of trials that started reached the finish line to date. In the past 5 years, 7 clinical trials started and 5 clinical trials were completed. i.e. 71.4% of trials that started reached the finish line.

Out of the total clinical trials conducted in "CH Agen" #1 sponsor was "University Hospital, Bordeaux" with 7 trials, followed by "French Society for Intensive Care" with 3 trials sponsored, "Janssen Research & Development, LLC" with 3 trials sponsored, "University Hospital, Angers" with 3 trials sponsored and "University Hospital, Brest" with 3 trials sponsored. Other sponsors include 9 different institutions and companies that sponsored additional 16 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "CH Agen" #1 collaborator was "European Organisation for Research and Treatment of Cancer - EORTC" with 2 trials as a collaborator, "Ministry of Health, France" with 2 trials as a collaborator, "University Hospital, Tours" with 2 trials as a collaborator, "Amgen" with 1 trials as a collaborator and "Aventis Pharmaceuticals" with 1 trials as a collaborator. Other collaborators include 26 different institutions and companies that were collaborators in the rest 36 trials.

According to Clinical.Site data, the most researched conditions in "CH Agen" are "Venous Thromboembolism" (3 trials), "Colorectal Cancer" (2 trials), "Influenza A" (2 trials), "Intensive Care Unit Syndrome" (2 trials) and "Acute Coronary Syndrome" (1 trials). Many other conditions were trialed in "CH Agen" in a lesser frequency.

Most popular intervention types in "CH Agen" are "Drug" (13 trials), "Other" (10 trials), "Procedure" (7 trials), "Device" (4 trials) and "Diagnostic Test" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (5 trials), "fluorouracil" (3 trials), "Pimodivir 600 mg" (2 trials), "SOC Treatment" (2 trials) and "leucovorin calcium" (2 trials). Other intervention names were less common.

The vast majority of trials in "CH Agen" are 32 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "CH Agen". undefined are not yet recruiting, 4 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 20 completed trials in CH Agen, undefined suspended trials, and 5 terminated clinical trials to date.

Out of the total trials that were conducted in CH Agen, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 12 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 8 trials that are defined as “Not Applicable".